Search research articles
Contact Us
Filters
Showing results (291-300 of 309) with videos related to
Page
of 31
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Cancer Research
|
February 14, 2018
Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis
Se Jin Oh, Hanbyoul Cho, Suhyun Kim, et al.
Oncotarget
|
September 30, 2015
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
Yoo-Young Lee, Hye-Kyung Jeon, Ji Eun Hong, et al.
Scientific Reports
|
March 19, 2020
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
E Sun Paik, Tae-Hyun Kim, Young Jae Cho, et al.
Gland Surgery
|
February 7, 2024
Initial experience with the enhanced recovery after surgery (ERAS) protocols in gynecologic surgery at an urban academic tertiary medical center
Won-Ji Kim, Joseph J Noh, Yu-Jeong Bang, et al.
Cancer Research and Treatment
|
January 6, 2017
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Eun Jin Heo, Young Jae Cho, William Chi Cho, et al.
Frontiers in Immunology
|
April 12, 2024
Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study
Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, et al.
Gynecologic Oncology
|
April 3, 2022
Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery
Hyunji Lim, Jung In Shim, Soo Jin Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
Natalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.
Cancer Research
|
July 19, 2017
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells
Kwon-Ho Song, Chel Hun Choi, Hyo-Jung Lee, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 309) with videos related to
Sort By:
Page
of 31
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Cancer Research
|
February 14, 2018
Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis
Se Jin Oh, Hanbyoul Cho, Suhyun Kim, et al.
Oncotarget
|
September 30, 2015
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
Yoo-Young Lee, Hye-Kyung Jeon, Ji Eun Hong, et al.
Scientific Reports
|
March 19, 2020
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
E Sun Paik, Tae-Hyun Kim, Young Jae Cho, et al.
Gland Surgery
|
February 7, 2024
Initial experience with the enhanced recovery after surgery (ERAS) protocols in gynecologic surgery at an urban academic tertiary medical center
Won-Ji Kim, Joseph J Noh, Yu-Jeong Bang, et al.
Cancer Research and Treatment
|
January 6, 2017
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Eun Jin Heo, Young Jae Cho, William Chi Cho, et al.
Frontiers in Immunology
|
April 12, 2024
Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study
Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, et al.
Gynecologic Oncology
|
April 3, 2022
Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery
Hyunji Lim, Jung In Shim, Soo Jin Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
Natalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.
Cancer Research
|
July 19, 2017
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells
Kwon-Ho Song, Chel Hun Choi, Hyo-Jung Lee, et al.
Page
of 31